Oscar Health Secures $475M Credit Facility and Projects Return to Profitability in 2026
Summary
Oscar Health secured a new $475 million revolving credit facility to enhance liquidity and announced its Q4 and full-year 2025 financial results, alongside strong 2026 guidance projecting a return to profitability and significant revenue growth.
Key Events
-
Secured $475 Million Revolving Credit Facility
Oscar Health entered into a new three-year secured revolving credit facility for $475 million, maturing in February 2029, to be used for general corporate purposes and to strengthen its balance sheet.
-
Reports Significant 2025 Losses
For the full year 2025, Oscar Health reported a net loss of $443.2 million and an Adjusted EBITDA loss of $279.8 million, a decline from profitability in 2024, primarily due to higher medical loss ratio and risk adjustment transfers.
-
Projects Strong Return to Profitability in 2026
The company provided optimistic 2026 financial guidance, forecasting total revenue of $18.7 billion to $19.0 billion and earnings from operations of $250 million to $450 million, indicating a significant turnaround from 2025 losses.
-
Improved Efficiency Metrics Forecasted for 2026
Oscar Health expects its Medical Loss Ratio to improve to 82.4%-83.4% and its SG&A Expense Ratio to decrease to 15.8%-16.3% in 2026, reflecting anticipated operational efficiencies.
Analysis
Oscar Health has announced a significant financial restructuring and provided forward-looking guidance that signals a strategic pivot towards profitability. The company secured a new $475 million secured three-year revolving credit facility, which substantially strengthens its balance sheet and provides crucial liquidity for general corporate purposes. This capital infusion is a positive development, especially following a challenging 2025. While the company reported a net loss of $443.2 million for the full year 2025 and a negative Adjusted EBITDA, its 2026 financial guidance is notably optimistic. Oscar Health projects total revenue between $18.7 billion and $19.0 billion, a significant increase from $11.7 billion in 2025, and anticipates a return to profitability with earnings from operations between $250 million and $450 million. The projected improvements in Medical Loss Ratio (82.4%-83.4%) and SG&A Expense Ratio (15.8%-16.3%) further underscore management's confidence in operational efficiency and a positive turnaround. This filing indicates a clear strategy to address past losses and achieve sustainable growth and profitability.
At the time of this filing, OSCR was trading at $12.17 on NYSE in the Finance sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $11.20 to $23.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.